首页> 美国卫生研究院文献>Case Reports in Gastroenterology >Metastatic Renal Cell Cancer and a Gastric Mass: An Unusual Finding
【2h】

Metastatic Renal Cell Cancer and a Gastric Mass: An Unusual Finding

机译:转移性肾细胞癌和胃肿块:一个不寻常的发现

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Renal cell cancer (RCC) accounts for approximately 3% of all adult malignancies. RCC has a metastasis rate of approximately 25%, which is most commonly to the lungs (>50%). On the contrary, RCC metastasis to the gastrointestinal tract (excluding the liver) is very uncommon and ranges from 0.2 to 0.7%. Thus, a gastric cancer in a patient with known metastatic RCC would most likely be secondary to metastasis. We present the first reported case of a metastatic RCC coexisting with a new-onset primary gastric cancer and a review of management using guidelines from metastatic RCC to the stomach. An 82-year-old African American male with papillary RCC status post left nephrectomy with recurrence of liver metastasis presented with failure to thrive shortly after his third cycle of chemotherapy despite stable disease by imaging studies. He had received 7 chemotherapy cycles of Gemzar, Nexavar, and Avastin prior to admission. He subsequently had a drop in his hemoglobin and was found to have hemoccult positive stool in the setting of recent Avastin. Endoscopic evaluation showed a 3 cm ulcerated mass in the cardia which was biopsied. The biopsy showed invasive and poorly differentiated gastric adenocarcinoma unrelated to his RCC. The patient subsequently underwent partial gastrectomy with loop gastrojejunostomy for resection of his stage 1 primary gastric adenocarcioma. The surgery also facilitated future chemotherapy (Avastin), which could not be given prior to surgery due to its side effect of bleeding. The patient did not receive adjuvant chemoradiation for his gastric cancer due to his comorbidities at the time and was doing well at a one month follow-up. Metastatic RCC and primary gastric cancer can coexist, especially when there is an overlap of risk factors such as smoking or nitrosamines. The management of a gastric cancer in the setting of metastatic RCC is similar to the management of solitary primary gastric carcinoma. Treatment of the primary gastric cancer can facilitate future chemotherapy such as Avastin, which has been recently approved for the treatment of metastatic RCC.
机译:肾细胞癌(RCC)约占所有成人恶性肿瘤的3%。 RCC的转移率约为25%,这最常见于肺部(> 50%)。相反,RCC转移到胃肠道(不包括肝脏)非常少见,范围为0.2%至0.7%。因此,患有已知转移性RCC的患者的胃癌很可能继发于转移。我们介绍了第一个报告的转移性RCC与新发原发性胃癌并存的病例,并使用从转移性RCC到胃的指南对治疗进行了回顾。一名82岁的非裔美国男性,左肾切除术后出现乳头状RCC,伴有肝转移复发,尽管影像学研究表明病情稳定,但在他的第三轮化疗后不久仍未能壮成长。入院前,他接受了Gemzar,Nexavar和Avastin的7个化疗周期。随后,他的血红蛋白下降,并且在最近的Avastin病情中被发现具有嗜血性粪便。内窥镜检查显示card门有3 cm溃疡性肿块,需进行活检。活检显示浸润性和低分化胃腺癌与他的RCC无关。该患者随后接受了部分胃切除术,并进行了环胃空肠吻合术,以切除他的1期原发性胃腺癌。手术还促进了未来的化学疗法(Avastin),由于其出血副作用,因此无法在手术前进行。由于当时的合并症,该患者未因胃癌接受辅助化学放疗,并且在一个月的随访中情况良好。转移性RCC和原发性胃癌可以共存,尤其是当吸烟或亚硝胺等危险因素重叠时。在转移性RCC背景下,胃癌的治疗与单纯原发性胃癌的治疗相似。原发性胃癌的治疗可以促进未来的化疗,例如阿瓦斯汀,最近已被批准用于治疗转移性RCC。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号